Summary of "We’ve been lied to about Vitamin K"
High-level conclusion
- Evidence that vitamin K reverses arterial plaque or calcification is mixed.
- Most randomized controlled trials (RCTs) show no effect on plaque or calcified plaque.
- Mechanistic data (matrix Gla protein carboxylation) and some long-term observational studies suggest a possible cardiovascular benefit, particularly for vitamin K2 and in higher‑risk populations.
- Overall: the balance of evidence leans toward a potential benefit for K2 against cardiovascular disease risk, but certainty is low.
Key scientific concepts and mechanisms
- Two types of cardiovascular plaque
- Soft (atherosclerotic) plaque — lipid-rich deposits targeted by RCTs.
- Calcified plaque — calcium‑deposited plaque often overlying soft plaque; measured separately.
- Matrix Gla protein (MGP)
- MGP is a vitamin K–dependent protein highly expressed in arteries undergoing calcification.
- Carboxylation (a vitamin K–dependent modification) activates MGP.
- Active (carboxylated) MGP inhibits pro‑calcification signaling and binds hydroxyapatite crystals, limiting calcium deposition.
- Vitamin K supplementation reliably reduces uncarboxylated (inactive) MGP across multiple studies, supporting biological plausibility that vitamin K could slow calcification.
- Discrepancy: despite consistent biochemical effects on MGP, most RCTs do not show reduced measured arterial calcification or plaque reversal.
Evidence overview (study types and findings)
- Systematic reviews and meta-analyses have synthesized multiple RCTs and observational studies.
- Randomized controlled trials (short- to multi-year)
- Majority report no effect on plaque or calcified plaque.
- A minority report benefit.
- Long-term observational cohorts (decades, e.g., ~21 years)
- Some analyses find higher vitamin K1 or K2 intake associated with reduced hospitalization for cardiovascular disease.
- Large meta-analysis (21 studies)
- Found associations for both K1 and K2 with reduced CVD risk, with a somewhat stronger signal for K2.
- Dietary measurement and confounding
- Studies that measure diet repeatedly and control rigorously for overall diet tend to weaken associations for K1 — suggesting K1 intake may be a marker for a healthy diet (green vegetables) rather than a causal factor.
- Evidence that K2 has an independent association with lower CVD risk is suggestive but comes from studies with weaker dietary confounding control.
Methodological factors that help explain conflicting results
- Dose: many negative trials used lower doses (< ~200 µg/day); trials reporting effects often used higher doses.
- Form: phylloquinone (K1) vs menaquinones (K2). K2 often shows a stronger signal; K1 effects may reflect overall healthier diets.
- Frequency/administration: infrequent dosing (e.g., several times per week) may reduce efficacy.
- Duration: short-term RCTs vs long-term observational follow-up — longer studies more often show associations not observed in short trials.
- Baseline health of participants: benefits more often reported in populations with metabolic dysfunction, chronic kidney disease, or established CVD (higher baseline risk).
- Confounding and dietary control: better control for diet often attenuates K1 associations; K2 studies sometimes lack equivalent adjustment.
- Outcome measures: biochemical surrogate (uncarboxylated MGP) vs imaging outcomes (plaque volume, calcification) vs clinical outcomes (hospitalization, CVD events). Biochemical improvements do not always translate to imaging or clinical benefits.
Practical details and takeaways
- Doses used in trials reporting effects: roughly 200–400 µg/day of vitamin K2.
- Safety: vitamin K is generally well tolerated.
- Important interaction: vitamin K can antagonize anticoagulant medications (e.g., warfarin). People on anticoagulants or with bleeding/clotting disorders should consult a physician before supplementing.
- Bottom-line interpretation
Don’t rely on short-term RCTs alone — but most RCTs do not support plaque or calcification reversal. Long-term observational data suggest reduced CVD risk with higher vitamin K (K1 and K2), but K1 effects are likely confounded by healthier diets. K2 shows a more consistent independent signal, though from studies with weaker methodology. Biological plausibility (MGP carboxylation) supports a potential role, but clinical outcome evidence is inconclusive.
If considering supplementation
- Evidence most suggestive for benefit: vitamin K2 (menaquinones).
- Commonly studied effective range in trials showing benefit: ~200–400 µg/day (K2).
- Caveat: check with a physician if taking anticoagulants or if you have bleeding/clotting disorders.
Concise methodology summary
- Outcomes studied: arterial plaque reversal, arterial calcification, overall cardiovascular disease events.
- Evidence sources: RCTs, systematic reviews/meta-analyses, long-term cohort studies.
- Key moderators to inspect in any study: dose, vitamin K type (K1 vs K2), dosing frequency, study duration, baseline health, control for dietary confounding, and outcome type (biochemical vs imaging vs clinical).
Researchers and sources referenced (as presented)
- Unnamed systematic review of nine trials (concluded lack of RCT evidence for surrogate cardiovascular benefit).
- Multiple randomized controlled trials (20+ studies analyzed by the presenter).
- Long-term cohort study example (~21 years) comparing vitamin K1 and K2 intake and CVD hospitalization risk.
- Systematic review and meta-analysis of 21 studies.
- The presenter’s deeper analysis and extended content (Physionic / “Physionic Insider”).
- General source types: randomized controlled trials, systematic reviews, meta-analyses, long-term observational cohort studies.
Notes and corrections
- The subtitles transcribed “MGK” / “matrix glin” — these should read matrix Gla protein (MGP).
- Hydroxyappatite should read hydroxyapatite.
Category
Science and Nature
Share this summary
Is the summary off?
If you think the summary is inaccurate, you can reprocess it with the latest model.
Preparing reprocess...